Symbols / SGMO
SGMO Chart
About
Sangamo Therapeutics, Inc., a clinical-stage genomic medicine company, focuses on translating science into medicines that transform the lives of patients and families afflicted with serious diseases in the United States. The company's clinical-stage product candidates are ST-920, a gene therapy product candidate, which is in Phase 1/2 clinical study for the treatment of Fabry disease; TX200, a chimeric antigen receptor engineered regulatory T cell (CAR-Treg) therapy product candidate that is in Phase 1/2 clinical study for the prevention of immune-mediated rejection in HLA-A2 mismatched kidney transplantation; and SB-525, a gene therapy product candidate, which is in Phase 3 clinical trial for the treatment of moderately severe to severe hemophilia A. Its preclinical development products focus on tauopathies, ALS/FTD, and huntington's diseases Sangamo Therapeutics, Inc. has collaborative and strategic partnerships with Biogen MA, Inc.; Kite Pharma, Inc.; Pfizer Inc.; Sanofi S.A.; Novartis Institutes for BioMedical Research, Inc.; Shire International GmbH; Dow AgroSciences LLC; Sigma-Aldrich Corporation; Genentech, Inc.; and Open Monoclonal Technology, Inc. The company was formerly known as Sangamo BioSciences, Inc. and changed its name to Sangamo Therapeutics, Inc. in January 2017. The company was incorporated in 1995 and is headquartered in Richmond, California.
Fundamentals
Scroll to Statements| Sector | Healthcare | Industry | Biotechnology | Market Cap | 181.75M |
| Enterprise Value | 154.80M | Income | -108.91M | Sales | 32.88M |
| Book/sh | 0.02 | Cash/sh | 0.09 | Dividend Yield | — |
| Payout | 0.00% | Employees | 183 | IPO | — |
| P/E | — | Forward P/E | -2.62 | PEG | — |
| P/S | 5.53 | P/B | 25.74 | P/C | — |
| EV/EBITDA | -1.48 | EV/Sales | 4.71 | Quick Ratio | 0.69 |
| Current Ratio | 0.88 | Debt/Eq | 407.24 | LT Debt/Eq | — |
| EPS (ttm) | -0.45 | EPS next Y | -0.19 | EPS Growth | — |
| Revenue Growth | -98.80% | Earnings | 2026-03-16 | ROA | -68.11% |
| ROE | -4.80% | ROIC | — | Gross Margin | -219.11% |
| Oper. Margin | -61.19% | Profit Margin | 0.00% | Shs Outstand | 371.68M |
| Shs Float | 329.83M | Short Float | 7.37% | Short Ratio | 4.18 |
| Short Interest | — | 52W High | 1.08 | 52W Low | 0.35 |
| Beta | 1.31 | Avg Volume | 6.24M | Volume | 5.68M |
| Target Price | $3.81 | Recom | Buy | Prev Close | $0.47 |
| Price | $0.49 | Change | 3.49% |
Valuation Models
Price estimates from analyst targets and simple models.
1. Analyst consensus
$3.81
Mean price target
2. Current target
$0.47
Latest analyst target
3. DCF / Fair value
$-1.88
Simplified: (Free Cash Flow ÷ Shares) × 18 (P/FCF multiple). Not a …
Ratings
Current target
$0.47
Low
$1.25
High
$10.00
Mean
$3.81
Latest analyst rating changes
| Date | Action | Analyst | Rating Change | Price Target |
|---|---|---|---|---|
| 2026-02-10 | reit | HC Wainwright & Co. | Buy → Buy | $10 |
| 2025-11-07 | down | Barclays | Overweight → Equal-Weight | $1 |
| 2025-09-04 | reit | HC Wainwright & Co. | Buy → Buy | $10 |
| 2025-06-24 | reit | HC Wainwright & Co. | Buy → Buy | $10 |
| 2025-05-14 | main | Barclays | Overweight → Overweight | $5 |
| 2025-04-07 | reit | HC Wainwright & Co. | Buy → Buy | $10 |
| 2025-03-18 | reit | RBC Capital | Sector Perform → Sector Perform | $2 |
| 2025-01-27 | reit | HC Wainwright & Co. | Buy → Buy | $10 |
| 2025-01-23 | main | Truist Securities | Buy → Buy | $5 |
| 2025-01-02 | reit | HC Wainwright & Co. | Buy → Buy | $10 |
| 2024-12-31 | main | Jefferies | Buy → Buy | $3 |
| 2024-12-31 | main | Wells Fargo | Equal-Weight → Equal-Weight | $2 |
| 2024-12-20 | reit | HC Wainwright & Co. | Buy → Buy | $10 |
| 2024-12-19 | reit | HC Wainwright & Co. | Buy → Buy | $10 |
| 2024-12-10 | reit | HC Wainwright & Co. | Buy → Buy | $10 |
| 2024-11-14 | reit | HC Wainwright & Co. | Buy → Buy | $10 |
| 2024-11-14 | main | Barclays | Overweight → Overweight | $9 |
| 2024-11-05 | main | HC Wainwright & Co. | Buy → Buy | $10 |
| 2024-10-23 | reit | HC Wainwright & Co. | Buy → Buy | $5 |
| 2024-10-22 | reit | HC Wainwright & Co. | Buy → Buy | $5 |
- One-time Fabry gene therapy lifts kidney function in early trial data - Stock Titan ue, 03 Feb 2026 08
- Sangamo Therapeutics (NASDAQ:SGMO) Downgraded by Wall Street Zen to Strong Sell - MarketBeat Sat, 31 Jan 2026 08
- Sangamo stock plunges after pricing $25 million dilutive offering - Investing.com ue, 03 Feb 2026 08
- What Makes Sangamo (SGMO) a New Buy Stock - Yahoo Finance hu, 14 Aug 2025 07
- Sangamo Therapeutics, Inc.'s (NASDAQ:SGMO) Share Price Boosted 29% But Its Business Prospects Need A Lift Too - simplywall.st ue, 03 Feb 2026 08
- Sangamo Therapeutics Prices Underwritten Offering of Common Stock and Warrants, Expected to Raise Approximately $25 Million - Quiver Quantitative ue, 03 Feb 2026 08
- Sangamo Therapeutics Inc (NASDAQ:SGMO) Stock Plummets 22% After Q3 Earnings Miss - ChartMill hu, 06 Nov 2025 08
- Sangamo plunges after pricing stock offering; principal financial officer exits - Seeking Alpha ue, 03 Feb 2026 08
- Sangamo’s Gene Therapy Ambitions Stunt Its Stock Performance - Finimize Sat, 30 Aug 2025 11
- How the Narrative Surrounding Sangamo Therapeutics Is Shifting After New Regulatory and Valuation Signals - Yahoo Finance Fri, 12 Dec 2025 08
- Companies Like Sangamo Therapeutics (NASDAQ:SGMO) Are In A Position To Invest In Growth - simplywall.st ue, 23 Sep 2025 07
- Sangamo stock holds Buy rating at H.C. Wainwright on positive Fabry disease data - Investing.com Fri, 05 Sep 2025 07
- Sangamo Therapeutics' (SGMO) Buy Rating Reiterated at HC Wainwright - MarketBeat ue, 10 Feb 2026 08
- Sangamo Therapeutics (SGMO) Shares Stabilize Amid Recent Key Pipeline Update - Yahoo Finance Mon, 12 Jan 2026 08
- Why Sangamo Therapeutics (SGMO) Is Down 21.1% After Steep Q3 Revenue Drop and Nasdaq Compliance Extension - Yahoo Finance Sun, 09 Nov 2025 08
Insider Transactions
| Date | Shares | Value | Url | Text | Insider | Position | Transaction | Start Date | Ownership |
|---|---|---|---|---|---|---|---|---|---|
| 0 | 25000 | — | — | Stock Award(Grant) at price 0.00 per share. | BEERS COURTNEY | Director | — | 2025-06-12 00:00:00 | D |
| 1 | 25000 | — | — | Stock Award(Grant) at price 0.00 per share. | HORN MARGARET A | Director | — | 2025-06-12 00:00:00 | D |
| 2 | 25000 | — | — | Stock Award(Grant) at price 0.00 per share. | MEYERS JAMES ROBERT | Director | — | 2025-06-12 00:00:00 | D |
| 3 | 25000 | — | — | Stock Award(Grant) at price 0.00 per share. | CAREY ROBERT F. | Director | — | 2025-06-12 00:00:00 | D |
| 4 | 25000 | — | — | Stock Award(Grant) at price 0.00 per share. | HILLAN KENNETH J. | Director | — | 2025-06-12 00:00:00 | D |
| 5 | 25000 | — | — | Stock Award(Grant) at price 0.00 per share. | SMITH KAREN LESLEY M.D. PH.D. | Director | — | 2025-06-12 00:00:00 | D |
| 6 | 25000 | — | — | Stock Award(Grant) at price 0.00 per share. | PARKER H STEWART | Director | — | 2025-06-12 00:00:00 | D |
| 7 | 25000 | — | — | Stock Award(Grant) at price 0.00 per share. | MARKELS JOHN | Director | — | 2025-06-12 00:00:00 | D |
| 8 | 120000 | — | — | Stock Award(Grant) at price 0.00 per share. | DURAIBABU PRATHYUSHA | Chief Financial Officer | — | 2025-02-25 00:00:00 | D |
| 9 | 120000 | — | — | Stock Award(Grant) at price 0.00 per share. | WILLOUGHBY SCOTT B | General Counsel | — | 2025-02-25 00:00:00 | D |
Financials
| Line Item | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
|---|---|---|---|---|
| TaxEffectOfUnusualItems | -9.40K | -2.99M | 0.00 | 0.00 |
| TaxRateForCalcs | 0.00 | 0.02 | 0.21 | 0.27 |
| NormalizedEBITDA | -83.57M | 58.21M | -180.72M | -165.70M |
| TotalUnusualItems | -5.52M | -155.01M | 0.00 | 0.00 |
| TotalUnusualItemsExcludingGoodwill | -5.52M | -155.01M | 0.00 | 0.00 |
| NetIncomeFromContinuingOperationNetMinorityInterest | -97.94M | -257.83M | -192.28M | -178.29M |
| ReconciledDepreciation | 9.36M | 22.19M | 20.56M | 17.64M |
| EBITDA | -89.09M | -96.80M | -180.72M | -165.70M |
| EBIT | -98.45M | -118.99M | -201.28M | -183.34M |
| NetInterestIncome | 5.86M | 11.10M | 9.43M | 5.35M |
| InterestIncome | 5.86M | 11.10M | 9.43M | 5.35M |
| NormalizedIncome | -92.43M | -105.81M | -192.28M | -178.29M |
| NetIncomeFromContinuingAndDiscontinuedOperation | -97.94M | -257.83M | -192.28M | -178.29M |
| TotalExpenses | 156.25M | 295.22M | 312.58M | 294.04M |
| TotalOperatingIncomeAsReported | -103.97M | -274.00M | -201.28M | -183.34M |
| DilutedAverageShares | 201.70M | 174.44M | 154.34M | 144.57M |
| BasicAverageShares | 201.70M | 174.44M | 154.34M | 144.57M |
| DilutedEPS | -0.49 | -1.48 | -1.25 | -1.23 |
| BasicEPS | -0.49 | -1.48 | -1.25 | -1.23 |
| DilutedNIAvailtoComStockholders | -97.94M | -257.83M | -192.28M | -178.29M |
| NetIncomeCommonStockholders | -97.94M | -257.83M | -192.28M | -178.29M |
| NetIncome | -97.94M | -257.83M | -192.28M | -178.29M |
| MinorityInterests | 0.00 | 0.00 | 11.00K | |
| NetIncomeIncludingNoncontrollingInterests | -97.94M | -257.83M | -192.28M | -178.30M |
| NetIncomeContinuousOperations | -97.94M | -257.83M | -192.28M | -178.30M |
| TaxProvision | -167.00K | -5.07M | 429.00K | 306.00K |
| PretaxIncome | -98.11M | -262.90M | -191.85M | -177.99M |
| OtherIncomeExpense | -5.52M | -155.01M | ||
| SpecialIncomeCharges | -5.52M | -155.01M | 0.00 | 0.00 |
| ImpairmentOfCapitalAssets | 5.52M | 155.01M | 0.00 | 0.00 |
| NetNonOperatingInterestIncomeExpense | 5.86M | 11.10M | 9.43M | 5.35M |
| InterestIncomeNonOperating | 5.86M | 11.10M | 9.43M | 5.35M |
| OperatingIncome | -98.45M | -118.99M | -201.28M | -183.34M |
| OperatingExpense | 156.25M | 295.22M | 312.58M | 294.04M |
| ResearchAndDevelopment | 111.52M | 234.06M | 249.90M | 230.82M |
| SellingGeneralAndAdministration | 44.73M | 61.17M | 62.68M | 63.22M |
| GeneralAndAdministrativeExpense | 44.73M | 61.17M | 62.68M | 63.22M |
| OtherGandA | 44.73M | 61.17M | 62.68M | 63.22M |
| TotalRevenue | 57.80M | 176.23M | 111.30M | 110.70M |
| OperatingRevenue | 57.80M | 176.23M | 111.30M | 110.70M |
| Line Item | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
|---|---|---|---|---|
| OrdinarySharesNumber | 212.84M | 178.13M | 166.79M | 145.92M |
| ShareIssued | 212.84M | 178.13M | 166.79M | 145.92M |
| TotalDebt | 30.57M | 38.10M | 43.11M | 48.08M |
| TangibleBookValue | 22.77M | 82.89M | 206.68M | 281.88M |
| InvestedCapital | 22.77M | 82.89M | 294.96M | 375.34M |
| WorkingCapital | 5.89M | 46.60M | 188.62M | 270.88M |
| NetTangibleAssets | 22.77M | 82.89M | 206.68M | 281.88M |
| CapitalLeaseObligations | 30.57M | 38.10M | 43.11M | 48.08M |
| CommonStockEquity | 22.77M | 82.89M | 294.96M | 375.34M |
| TotalCapitalization | 22.77M | 82.89M | 294.96M | 375.34M |
| TotalEquityGrossMinorityInterest | 22.77M | 82.89M | 294.96M | 375.34M |
| MinorityInterest | 0.00 | 0.00 | 0.00 | |
| StockholdersEquity | 22.77M | 82.89M | 294.96M | 375.34M |
| GainsLossesNotAffectingRetainedEarnings | -7.53M | -4.59M | -8.40M | -3.99M |
| OtherEquityAdjustments | -7.53M | -4.59M | -8.40M | -3.99M |
| RetainedEarnings | -1.50B | -1.41B | -1.15B | -956.27M |
| AdditionalPaidInCapital | 1.53B | 1.49B | 1.45B | 1.33B |
| CapitalStock | 2.13M | 1.78M | 1.67M | 1.46M |
| CommonStock | 2.13M | 1.78M | 1.67M | 1.46M |
| PreferredStock | 0.00 | 0.00 | 0.00 | 0.00 |
| TotalLiabilitiesNetMinorityInterest | 78.86M | 82.43M | 267.55M | 346.58M |
| TotalNonCurrentLiabilitiesNetMinorityInterest | 33.06M | 34.70M | 155.84M | 218.69M |
| OtherNonCurrentLiabilities | 933.00K | 1.19M | 1.21M | 1.22M |
| NonCurrentDeferredLiabilities | 5.87M | 0.00 | 115.65M | 173.42M |
| NonCurrentDeferredRevenue | 5.87M | 0.00 | 109.38M | 166.78M |
| NonCurrentDeferredTaxesLiabilities | 0.00 | 6.27M | 6.64M | |
| LongTermDebtAndCapitalLeaseObligation | 26.25M | 33.52M | 38.99M | 44.05M |
| LongTermCapitalLeaseObligation | 26.25M | 33.52M | 38.99M | 44.05M |
| CurrentLiabilities | 45.80M | 47.73M | 111.71M | 127.89M |
| CurrentDeferredLiabilities | 7.56M | 0.00 | 51.78M | 85.71M |
| CurrentDeferredRevenue | 7.56M | 0.00 | 51.78M | 85.71M |
| CurrentDebtAndCapitalLeaseObligation | 4.31M | 4.59M | 4.12M | 4.03M |
| CurrentCapitalLeaseObligation | 4.31M | 4.59M | 4.12M | 4.03M |
| PensionandOtherPostRetirementBenefitPlansCurrent | 14.57M | 8.92M | 21.51M | 20.84M |
| PayablesAndAccruedExpenses | 19.37M | 34.22M | 34.30M | 17.31M |
| CurrentAccruedExpenses | 3.88M | 18.96M | 11.88M | 7.55M |
| Payables | 15.48M | 15.26M | 22.42M | 9.76M |
| AccountsPayable | 15.48M | 15.26M | 22.42M | 9.76M |
| TotalAssets | 101.64M | 165.32M | 562.51M | 721.92M |
| TotalNonCurrentAssets | 49.94M | 70.99M | 262.18M | 323.15M |
| OtherNonCurrentAssets | 2.38M | 2.77M | 18.52M | 16.82M |
| NonCurrentAccountsReceivable | 12.81M | 15.36M | ||
| InvestmentsAndAdvances | 0.00 | 29.84M | 88.17M | |
| InvestmentinFinancialAssets | 0.00 | 29.84M | 88.17M | |
| AvailableForSaleSecurities | 88.17M | |||
| GoodwillAndOtherIntangibleAssets | 0.00 | 88.28M | 93.46M | |
| OtherIntangibleAssets | 50.73M | 53.76M | ||
| Goodwill | 0.00 | 37.55M | 39.70M | |
| NetPPE | 34.76M | 52.87M | 125.53M | 124.70M |
| AccumulatedDepreciation | -39.82M | -51.05M | -36.53M | -25.02M |
| GrossPPE | 74.57M | 103.91M | 162.06M | 149.73M |
| Leases | 24.92M | 29.81M | 30.57M | 21.97M |
| ConstructionInProgress | 0.00 | 1.09M | 14.77M | 4.73M |
| OtherProperties | 46.10M | 68.41M | 110.99M | 113.95M |
| MachineryFurnitureEquipment | 3.55M | 4.61M | 5.73M | 9.08M |
| Properties | 0.00 | 0.00 | 0.00 | 0.00 |
| CurrentAssets | 51.69M | 94.33M | 300.33M | 398.77M |
| OtherCurrentAssets | 5.17M | 9.26M | 18.22M | 15.86M |
| PrepaidAssets | 18.22M | 15.86M | ||
| Receivables | 4.60M | 4.07M | 4.47M | 6.36M |
| TaxesReceivable | 4.07M | 3.14M | ||
| AccruedInterestReceivable | 403.00K | 794.00K | 349.00K | |
| AccountsReceivable | 526.00K | 923.00K | 3.68M | 6.01M |
| CashCashEquivalentsAndShortTermInvestments | 41.92M | 81.00M | 277.63M | 376.55M |
| OtherShortTermInvestments | 0.00 | 35.80M | 177.19M | 197.68M |
| CashAndCashEquivalents | 41.92M | 45.20M | 100.44M | 178.87M |
| Line Item | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
|---|---|---|---|---|
| FreeCashFlow | -67.41M | -246.00M | -243.80M | -256.53M |
| IssuanceOfCapitalStock | 28.99M | 15.11M | 84.87M | 27.10M |
| CapitalExpenditure | -267.00K | -21.16M | -20.17M | -23.28M |
| EndCashPosition | 43.42M | 46.70M | 101.94M | 180.37M |
| BeginningCashPosition | 46.70M | 101.94M | 180.37M | 132.83M |
| EffectOfExchangeRateChanges | -2.05M | 1.48M | 1.25M | -263.00K |
| ChangesInCash | -1.24M | -56.72M | -79.68M | 47.81M |
| FinancingCashFlow | 28.38M | 14.59M | 84.66M | 32.86M |
| CashFlowFromContinuingFinancingActivities | 28.38M | 14.59M | 84.66M | 32.86M |
| NetOtherFinancingCharges | -904.00K | -1.45M | -2.10M | -3.26M |
| ProceedsFromStockOptionExercised | 290.00K | 935.00K | 1.90M | 9.02M |
| NetCommonStockIssuance | 28.99M | 15.11M | 84.87M | 27.10M |
| CommonStockIssuance | 28.99M | 15.11M | 84.87M | 27.10M |
| InvestingCashFlow | 37.52M | 153.53M | 59.28M | 248.20M |
| CashFlowFromContinuingInvestingActivities | 37.52M | 153.53M | 59.28M | 248.20M |
| NetOtherInvestingChanges | 1.95M | |||
| NetInvestmentPurchaseAndSale | 35.84M | 174.69M | 79.46M | 271.60M |
| SaleOfInvestment | 35.84M | 234.24M | 356.85M | 609.75M |
| PurchaseOfInvestment | 0.00 | -59.55M | -277.39M | -338.16M |
| NetBusinessPurchaseAndSale | 0.00 | 0.00 | -119.00K | |
| PurchaseOfBusiness | 0.00 | 0.00 | -119.00K | |
| NetPPEPurchaseAndSale | -267.00K | -21.16M | -20.17M | -23.28M |
| PurchaseOfPPE | -267.00K | -21.16M | -20.17M | -23.28M |
| OperatingCashFlow | -67.14M | -224.84M | -223.63M | -233.25M |
| CashFlowFromContinuingOperatingActivities | -67.14M | -224.84M | -223.63M | -233.25M |
| ChangeInWorkingCapital | 4.51M | -164.03M | -82.32M | -101.89M |
| ChangeInOtherWorkingCapital | 13.43M | -161.16M | -90.39M | -83.83M |
| ChangeInOtherCurrentLiabilities | -5.83M | -5.06M | -2.26M | -3.12M |
| ChangeInPayablesAndAccruedExpense | -8.43M | -7.10M | 13.35M | -7.66M |
| ChangeInAccruedExpense | 5.74M | -12.69M | ||
| ChangeInPayable | -14.17M | 5.59M | ||
| ChangeInAccountPayable | -14.17M | 5.59M | ||
| ChangeInPrepaidAssets | 4.38M | 10.26M | -4.91M | -7.17M |
| ChangeInReceivables | 953.00K | -976.00K | 1.89M | -103.00K |
| ChangesInAccountReceivables | 397.00K | 2.75M | 2.33M | -789.00K |
| OtherNonCashItems | 330.00K | 1.12M | -6.50M | |
| StockBasedCompensation | 12.38M | 27.36M | 31.65M | 32.96M |
| AssetImpairmentCharge | 5.52M | 155.01M | 0.00 | 0.00 |
| AmortizationOfSecurities | -273.00K | -2.33M | -1.24M | 2.84M |
| DeferredTax | 0.00 | -6.33M | 0.00 | 0.00 |
| DeferredIncomeTax | 0.00 | -6.33M | 0.00 | 0.00 |
| DepreciationAmortizationDepletion | 9.36M | 22.19M | 20.56M | 17.64M |
| DepreciationAndAmortization | 9.36M | 22.19M | 20.56M | 17.64M |
| Depreciation | 9.36M | 22.19M | 20.56M | 17.64M |
| OperatingGainsLosses | -1.03M | -70.00K | ||
| GainLossOnInvestmentSecurities | -1.03M | -18.00K | ||
| GainLossOnSaleOfPPE | 0.00 | -52.00K | ||
| NetIncomeFromContinuingOperations | -97.94M | -257.83M | -192.28M | -178.30M |
SEC Filings
Recent 10-K, 10-Q, 8-K, and Form 4 (insider) filings.
Public Trades for SGMO
| Date | User | Asset | Broker | Type | Position Size | Entry Price | Patterns |
|---|